Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink

Kimberly G Blumenthal^{1

2

3}, Neelam A Phadke^{1

2}, David W Bates^{2

4

5}

Affiliations

¹ Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.
³ Mongan Institute, Massachusetts General Hospital, Boston.
⁴ Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Editorial

Kimberly G Blumenthal et al. JAMA. 2021.

. 2021 Oct 12;326(14):1375-1377.

doi: 10.1001/jama.2021.14808.

Kimberly G Blumenthal^{1

2

3}, Neelam A Phadke^{1

2}, David W Bates^{2

4

5}

¹ Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston.
² Harvard Medical School, Boston, Massachusetts.
³ Mongan Institute, Massachusetts General Hospital, Boston.
⁴ Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

No abstract available

Comment on

Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, Xu S, Yih WK, Glanz JM, Williams JTB, Hambidge SJ, Lewin BJ, Shimabukuro TT, DeStefano F, Weintraub ES. Klein NP, et al. JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072. JAMA. 2021. PMID: 34477808 Free PMC article.